Novel Antiaging Regenerative Skin Care Regimen Containing Human Platelet Extract (HPE)

NCT05457491 | Terminated Phase 1 Results FDA Drug

• 1 other identifier: 21-008529
• Study Type: interventional
• Target: 56
• Locations: 1 country
• Sites: 1

Brief Summary

The Researchers are trying to study a cosmetic skin care product called human platelet extract (HPE) to see if it can be used as a possible treatment for skin anti-aging and skin rejuvenation. They are trying find out the safety and tolerability of topical HPE after multiple doses of topical administration

Conditions

Skin Aging

Outcome Measures

Primary Outcomes (5)

• Change in Redness Area

  The percentage of participants to experience at least 50% improvement in redness area over baseline. As measured by photodocumentation with the VISIA-CR Generation 5 3D PRIMOS using RBX technology. Redness pixel variation and the cross polarized image were transformed into red images that correlated with hemoglobin absorption/distribution.

  baseline, 6 weeks

• Change Brown Spot Area

  Photodocumentation with the VISIA-CR Generation 5 3D PRIMOS to assess overall variation in color values specifically pixel variation across defined cosmetic subunits and how rapidly those colors change spatially within it, producing a score from 0 to 1, where 0 is less melanin or brown color and 1 is more melanin or brown color. Lower scores reflect better outcomes.

  baseline, 6 weeks

• Change in Luminosity

  Luminosity (color intensity) is the measure of the light reflected from the skin surface. Photodocumentation with the VISIA-CR Generation 5 3D PRIMOS to assess overall variation in color values specifically pixel variation across defined cosmetic subunits and how rapidly those colors change spatially within it. Lower values reflect dull and/or uneven skin tones. Higher values reflect radiant and/or even-appearing skin tones.

  baseline, 6 weeks

• Change in Color Evenness

  Photodocumentation with the VISIA-CR Generation 5 3D PRIMOS to assess overall variation in color values specifically pixel variation across defined cosmetic subunits and how rapidly those colors change spatially within it, producing a score from 0 to 1, where 0 is dull and/or uneven skin tone and 1 is radiant and/or even-appearing skin tone. Higher scores reflect better outcomes.

  baseline, 6 weeks

• Change in Wrinkles Area

  Photodocumentation with the VISIA-CR Generation 5 3D PRIMOS to assess forehead wrinkles using 3D fringe projection which evaluates static wrinkles and measures the difference in fractional area change

  baseline, 6 weeks

Secondary Outcomes (5)

• Cosmetic Skin Improvement

  12 weeks

• Satisfaction With Topical Cosmetic Treatment

  12 weeks

• Recommendation of Topical Cosmetic Treatment

  12 weeks

• Likelihood of Continuing Topical Cosmetic Treatment

  6 weeks

• Topical Cosmetic Treatment on Self-esteem

  12 weeks

Study Arms (1)

Human platelet extract (HPE)

EXPERIMENTAL

Subjects will follow a standardized twice daily skin care regimen of applying morning and night. Morning skin care routine includes Vanicream Gentle Facial Cleanser, human platelet extract, and EltaMD UV Daily Broad-Spectrum SPF 40, or Vanicream Lite Lotion. Evening skin care routine includes Vanicream Gentle Facial cleanser, human platelet extract, and EltaMD PM Therapy Facial Moisturizer or Vanicream Lite Lotion

Biological: Human platelet extract (cosmetic product); Other: Vanicream Gentle Facial Cleanser; Other: EltaMD UV Daily Broad-Spectrum SPF 40; Other: EltaMD PM Therapy Facial Moisturizer; Other: Vanicream Lite Lotion

Interventions

Human platelet extract (cosmetic product) BIOLOGICAL

A leukocyte depleted allogeneic product derived from human U.S. sourced pooled apheresed platelets (derived from screened healthy donors). Applied to face twice daily for 12 weeks.

Human platelet extract (HPE)

Vanicream Gentle Facial Cleanser OTHER

A mild cleanser specifically formulated for daily facial use. Applied to face twice daily for 12 weeks

Human platelet extract (HPE)

EltaMD UV Daily Broad-Spectrum SPF 40 OTHER

A daily moisturizer with a lightweight formula that provides broad-spectrum sunscreen protection. EltaMD UV Daily Broad-Spectrum SPF 40 provides powerful protection against the sun's harmful UV rays, as it hydrates and is gentle enough for post-procedure skin. Powered by hyaluronic acid, this face sunscreen plumps the skin with lightweight moisture, while micronized zinc and octinoxate shield skin from UVA/UVB rays to prevent the visible signs of environmentally caused aging. Applied to face once daily for 12 weeks.

Human platelet extract (HPE)

EltaMD PM Therapy Facial Moisturizer OTHER

A fortifying face moisturizer to repair elasticity and vitality. EltaMD PM Therapy Facial Moisturizer restores youthfulness while strengthening the skin's natural moisture barrier. Niacinamide blends with antioxidants to boost the skin color and tone, as it speeds up the skin's repair processes. Rice protein peptides aid in encouraging cell growth, promoting collagen formation and improving elasticity. Applied to face once daily for 12 weeks.

Human platelet extract (HPE)

Vanicream Lite Lotion OTHER

Lotion to restore and maintain a normal moisture level. Applied to face twice daily for 12 weeks.

Human platelet extract (HPE)

Eligibility Criteria

• Age: 18 Years - 85 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Persons of childbearing potential must have a negative pregnancy test prior to receiving the study product and will agree to use adequate contraception (hormonal or barrier method or abstinence) from the time of screening to a period of 2 years until discontinuation of treatment. Females of childbearing potential are defined as premenopausal and not surgically sterilized, or post-menopausal for fewer than 2 years. A urine pregnancy test will be performed prior to the administration of the study product to confirm negative results. If the urine pregnancy test is positive, the study product will not be administered, and the result will be confirmed by a serum pregnancy test. Urine pregnancy tests will be performed by qualified personnel using kit. Persons becoming pregnant during the study will continue to be monitored for the duration of the study or completion of the pregnancy, whichever is longer. Monitoring will include perinatal and neonatal outcome. Any Serious Adverse Events (SAE) associated with pregnancy will be recorded.
• All skin phototypes ≥ grade I of Fitzpatrick's classification.
• Mild-to-moderate global face wrinkles and mild-to-moderate global fine lines based on a modified Griffiths' 10-point scale \[3\].
• Fully understanding of the requirements of the study and willingness to comply with the treatment plan, including laboratory tests, diagnostic imaging, and follow-up visits and assessments.
• Volunteer willingness to discontinue any other anti-aging topical or parenteral treatments for the duration of the study.
• Can provide written informed consent and complete HIPAA documentation after the nature of the study is fully explained and prior to any study-related treatment.
• Can provide written informed consent to being photographed for purposes of treatment for medical, scientific purposes.

You may not qualify if:

• Pregnant or nursing, or planning on becoming pregnant during the study period
• Subjects who have had an antiaging or aesthetic treatment prior to the study: Botox or Botox-like products, peelings, plastic surgery, resurfacing with Laser, Intense pulsed light (IPL) therapy, threats, radiofrequency treatments, hyaluronic acid treatment, Plasma-Rich Platelets treatment, or any other specific treatments prone to change the skin aspect during the last 6 months
• Individuals with a history of any dermatological disease or condition, including but not limited to active atopic dermatitis, psoriasis, eczema, active seasonal allergies, collagen diseases, or skin cancer involving the treated sites within the past 6 months
• Cutaneous marks on the experimental area which could interfere with the assessment of skin reactions (pigmentation problems, scar elements, over-developed pilosity, ephelides, and nevi in too great quantity, sunburn, beauty spots, freckles, etc.)
• Participants with asymmetric photodamage on dorsal hands due to environmental exposures (i.e., golfing) and/or other skin lesions including burns or scars resulting in significant skin surface variability between dorsal hands
• Eczematous reaction still visible, scar, or pigmentary sequelae of previous tests on the experimental area
• Allergy to colophony or nickel.
• Allergy or reactivity to drugs, food or cosmetic products previously observed, including perfumes or cologne products.
• Skin hyper-reactivity.
• Forecast of intensive sun, tanning bed use or UV phototherapy during the test period.
• Treatment with prescription-strength Vitamin A acid or its derivatives within 3 months before the beginning of the study.
• Treatment with topical steroids on the experimental area within 16 days before the study.
• Study constraints:
• No application of products on the experimental area (except the suggested ones), particularly any anti-aging cosmetic products except for sunscreen.
• No change in hygiene habits

Sponsors & Collaborators

• Mayo Clinic: lead

Study Sites (1)

Mayo Clinic

Rochester, Minnesota, 55905, United States

Location

MeSH Terms

Interventions

Cosmetics

Intervention Hierarchy (Ancestors)

Specialty Uses of Chemicals; Chemical Actions and Uses; Household Products; Technology, Industry, and Agriculture

Limitations and Caveats

Study was terminated early per Principal Investigator

Results Point of Contact

• Title: Saranya P. Wyles, M.D., Ph.D.
• Organization: Mayo Clinic

Wyles.Saranya@mayo.edu

507-284-5475

Study Officials

• Saranya P Wyles, M.D., Ph.D.

  Mayo Clinic

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: Yes

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: OTHER
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: July 11, 2022
• First Posted: July 14, 2022
• Study Start: October 1, 2021
• Primary Completion: July 7, 2022
• Study Completion: July 7, 2022
• Last Updated: October 4, 2024
• Results First Posted: October 4, 2024

Record last verified: 2024-09

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)